Evidence map›Paper›PMID 33442541›Full record

ArticleLiver cancer2020

The Real Impact of Bridging or Downstaging on Survival Outcomes after Liver Transplantation for Hepatocellular Carcinoma.

Sunyoung Lee, Kyoung Won Kim, Gi-Won Song, Jae Hyun Kwon, Shin Hwang, Ki-Hun Kim, Chul-Soo Ahn, Deok-Bog Moon, Gil-Chun Park, Sung-Gyu Lee

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Liver cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
3.3field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 35 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Sunyoung LeeDepartment of Radiology and Research Institute of Radiological Science, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.
Kyoung Won KimDepartment of Radiology and Research Institute of Radiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Gi-Won SongDepartment of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Jae Hyun KwonDepartment of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Shin HwangDepartment of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Ki-Hun KimDepartment of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Chul-Soo AhnDepartment of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Deok-Bog MoonDepartment of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Gil-Chun ParkDepartment of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Sung-Gyu LeeDepartment of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Asan Medical Center · KRUlsan College · KRUniversity of Ulsan · KRYonsei University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThere is no consensus regarding selection criteria on liver transplantation (LT) for hepatocellular carcinoma (HCC), especially for living donor liver transplantation, although emerging evidence has been found for the effectiveness of bridging or downstaging.

objectiveWe evaluated the long-term outcomes of patients who underwent LT with or without bridging or downstaging for HCC.

methodsThis retrospective study included 896 LT recipients with HCC between June 2005 and May 2015. Recurrence-free survival (RFS), overall survival (OS), and their associated factors were evaluated.

resultsThe 5-year RFS in the full cohort of 896 patients was 82.4%, and the OS was 85.3%. In patients with initial Organ Procurement and Transplantation Network (OPTN) T1 and T2, the 5-year RFS and OS did not significantly differ between LT groups with and without bridging (all

conclusionsThe impact of bridging therapy on survival outcomes is limited in patients with early-stage HCC, whereas OPTN T1 or T2 with progression provides worse prognosis. OPTN T3 should undergo LT after successful downstaging, and OPTN T3 with successful downstaging allows for acceptable long-term posttransplant outcomes.

Indexed as

Liver cancermRECISTRecurrenceSurvivalTransplantation

Identifiers

PMID33442541
PMCPMC7768098
OpenAlexW3095353485

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.